WO2005103231A3 - Mit toxischen substanzen beladene dendritische zellen zur behandlung von nierenzellkarzinomen - Google Patents

Mit toxischen substanzen beladene dendritische zellen zur behandlung von nierenzellkarzinomen Download PDF

Info

Publication number
WO2005103231A3
WO2005103231A3 PCT/DE2005/000719 DE2005000719W WO2005103231A3 WO 2005103231 A3 WO2005103231 A3 WO 2005103231A3 DE 2005000719 W DE2005000719 W DE 2005000719W WO 2005103231 A3 WO2005103231 A3 WO 2005103231A3
Authority
WO
WIPO (PCT)
Prior art keywords
kidney cell
cell carcinomas
order
toxic substances
treat kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2005/000719
Other languages
English (en)
French (fr)
Other versions
WO2005103231A2 (de
Inventor
Dirk Weickmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toximed GmbH
Original Assignee
Toximed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toximed GmbH filed Critical Toximed GmbH
Priority to DE112005001476T priority Critical patent/DE112005001476A5/de
Publication of WO2005103231A2 publication Critical patent/WO2005103231A2/de
Anticipated expiration legal-status Critical
Publication of WO2005103231A3 publication Critical patent/WO2005103231A3/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmazeutischer Wirkstoff zur Behandlung von Nierenzellkarzinomen durch dendritische Zellen, die in Anwesenheit von Leukin kultiviert wurden und beladen sind mit Toxinen die aus dem Giftcocktail von Spinnen der Gattung Loxosceles, Scytodiae oder Drymusa gewonnen wurden, sowie Verfahren zur Herstellung dieser Zellen.
PCT/DE2005/000719 2004-04-21 2005-04-20 Mit toxischen substanzen beladene dendritische zellen zur behandlung von nierenzellkarzinomen Ceased WO2005103231A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112005001476T DE112005001476A5 (de) 2004-04-21 2005-04-20 Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004019323.1 2004-04-21
DE102004019323A DE102004019323A1 (de) 2004-04-21 2004-04-21 Mit toxischen Substanzen beladene dendritische Zellen zur Behandlung von Nierenzellkarzinomen

Publications (2)

Publication Number Publication Date
WO2005103231A2 WO2005103231A2 (de) 2005-11-03
WO2005103231A3 true WO2005103231A3 (de) 2006-12-28

Family

ID=34993192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/000719 Ceased WO2005103231A2 (de) 2004-04-21 2005-04-20 Mit toxischen substanzen beladene dendritische zellen zur behandlung von nierenzellkarzinomen

Country Status (2)

Country Link
DE (2) DE102004019323A1 (de)
WO (1) WO2005103231A2 (de)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001823A2 (en) * 1998-07-02 2000-01-13 Immunex Corporation Flt3-l mutants and methods of use
WO2001043754A2 (de) * 1999-12-17 2001-06-21 Mack, Gerd, R. Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen
WO2001087346A2 (de) * 2000-05-17 2001-11-22 Toximed Gmbh Mit toxischen substanzen beladene dendritische zellen
WO2001088105A2 (de) * 2000-05-17 2001-11-22 Toximed Gmbh Herstellung von dendritischen zellen aus rückenmarkstammzellen
WO2003006055A2 (en) * 2001-05-14 2003-01-23 Duotol Ab Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
WO2004074451A2 (en) * 2003-02-18 2004-09-02 Maxcyte, Inc. Loading of cells with antigens by electroporation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001823A2 (en) * 1998-07-02 2000-01-13 Immunex Corporation Flt3-l mutants and methods of use
WO2001043754A2 (de) * 1999-12-17 2001-06-21 Mack, Gerd, R. Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen
WO2001087346A2 (de) * 2000-05-17 2001-11-22 Toximed Gmbh Mit toxischen substanzen beladene dendritische zellen
WO2001088105A2 (de) * 2000-05-17 2001-11-22 Toximed Gmbh Herstellung von dendritischen zellen aus rückenmarkstammzellen
WO2003006055A2 (en) * 2001-05-14 2003-01-23 Duotol Ab Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
WO2004074451A2 (en) * 2003-02-18 2004-09-02 Maxcyte, Inc. Loading of cells with antigens by electroporation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCI MOWAT A ET AL: "ORAL VACCINATION WITH IMMUNE STIMULATING COMPLEXES", IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 65, 1999, pages 133 - 140, XP002906832, ISSN: 0165-2478 *

Also Published As

Publication number Publication date
WO2005103231A2 (de) 2005-11-03
DE102004019323A1 (de) 2005-11-10
DE112005001476A5 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2006113679A3 (en) Delivery of sirna by neutral lipid compositions
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
GB0621241D0 (en) Ion binding compositions
WO2007022519A3 (en) Steerable heart implants for congestive heart failure
WO2008082669A3 (en) Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
WO2004081185A3 (en) Methods to enhance the activity of lignocellulose-degrading enzymes
WO2002024865A3 (en) Modulation of secondary metabolite production by zinc binuclear cluster proteins
WO2007033281A3 (en) Ion exchange resin treated to control swelling
WO2008027420A3 (en) Implantable devices for producing insulin
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2007117490A3 (en) Antibody purification
WO2007011390A3 (en) Large-scale production of human serum butyrylcholinesterase as a bioscavenger
WO2006076651A3 (en) Treatment method
WO2007002376A3 (en) Method of preparing electrode
WO2007027999A3 (en) Chemical compounds
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
WO2005108428A3 (en) Cd40 splice variants and their uses
WO2005095652A3 (en) Pnmt as a novel marker for progenitor cells
WO2009023544A3 (en) Dosage unit anion-exchange polymer pharmaceutical compositions
WO2010032008A3 (en) Dendritic cell modulatory molecule
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2008107471A3 (en) Modified hydroxypolymer conjugates with killing effect on tumor cells
WO2005017100A8 (en) Ribonucleases and methods of making them recombinantly
WO2006071746A3 (en) Engineered dopamine neurons and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1120050014762

Country of ref document: DE

122 Ep: pct application non-entry in european phase
REF Corresponds to

Ref document number: 112005001476

Country of ref document: DE

Date of ref document: 20070524

Kind code of ref document: P